drugset / Trial / NCT06778265
An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's Disease
Phase 1
Active not recruiting
12 enrolled
Shanghai UniXell Biotechnology Co., Ltd
Ruijin Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This clinical study is designed to explore the safety and tolerability of UX-DA001. It will also explore if UX-DA001 works to improve motor function in subjects with Parkinson's disease. UX-DA001 manufactured from participant's own cells will differentiate into mature dopaminergic neurons after being transplanted into the brain of the participant.
Timeline
- Start
- 2025-03-01
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UX-DA001 | Cell therapy | — | Other |